Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

DiaSorin S.p.A.. (7/14/16). "Press Release: DiaSorin Increases Diagnostic Test Menu for Molecular Screening of Acute Myeloid Leukemia". Saluggia.

Region Region Europe
Organisation Organisation DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA)
  Group DiaSorin (Group)
Products Product Iam AML1-ETO genetic test
  Product 2 Liaison analyzer
Person Person Eros, Paul (DiaSorin 201607 VP International Marketing for DiaSorin Molecular)

Early stratification of patient risk through effective screening will facilitate timely and effective implementation of therapy leading to improved patient management.

DiaSorin (FTSE Mid Cap: DIA) launches a new CE-IVD molecular diagnostic test, Iam AML1-ETO (not available in the USA) for the identification of the one of the most common genetic causes of Acute Myeloid Leukemia.

The new test allows reliable, easy and extremely fast (11 minutes instead of nearly 4 hours) detection of the AML1-ETO translocation, which is one of the most common genetic causes of “Acute Myeloid Leukemia”.

Whilst this translocation is associated with a good prognosis, poor risk stratification results in less than 50% of patients reaching a complete remission. Rapid molecular identification of the translocation is therefore crucial for therapeutic decision making.

Identification of risk groups, in a timely and reliable manner, by genetic means represents a unique opportunity for implementing effective therapy. This is especially important in older patient populations who may not be eligible for bone marrow transplantation.

The short time taken to complete the DiaSorin test will provide medical staff with key information to initiate the correct treatment for their patients.

The Iam AML1-ETO will represent the optimal solution for reliable, rapid and simple molecular screening of AML at diagnosis.

Paul Eros, Vice President of International Marketing for DiaSorin Molecular, commented: “With the launch of this assay DiaSorin shows its commitment to providing innovative molecular solutions to aid in clinical decision making” he went on to add “That this third assays, following the earlier launches of Iam BCR-ABL and Iam PML-RARA, has been made possible as a result of very strong collaboration in research and development between DiaSorin and key opinion leaders in the field of hematological malignancy”.


Assay name: AML1 - ETO

Diagnosis: Acute Myeloid Leukemia

Immunodiagnostics Molecular Diagnostics

Clinical area:

Infectious Diseases
Hepatitis & Retrovirus
Oncology & Endocrinology
Bone & Mineral
Cardiac Markers
GI Stool Testing

Infectious Disease

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel. +39.0161.487.988

Ines Di Terlizzi
Investor Relator
Tel. +39.0161.487.567

About DiaSorin:

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For more information, visit

Record changed: 2016-07-18


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for DiaSorin (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top